Key Insights

Highlights

Success Rate

97% trial completion (above average)

Research Maturity

65 completed trials (43% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

1.3%

2 terminated out of 150 trials

Success Rate

97.0%

+10.5% vs benchmark

Late-Stage Pipeline

13%

19 trials in Phase 3/4

Results Transparency

14%

9 of 65 completed with results

Key Signals

9 with results97% success

Data Visualizations

Phase Distribution

137Total
Not Applicable (71)
P 1 (28)
P 2 (19)
P 3 (13)
P 4 (6)

Trial Status

Completed65
Recruiting37
Active Not Recruiting19
Unknown13
Not Yet Recruiting7
Enrolling By Invitation4

Trial Success Rate

97.0%

Benchmark: 86.5%

Based on 65 completed trials

Clinical Trials (150)

Showing 20 of 20 trials
NCT07736391Phase 1Active Not RecruitingPrimary

A Study of SYH2069 Injection in Healthy Participants

NCT07736404Phase 1Active Not RecruitingPrimary

A Study of SYH2082 Injection in Healthy Participants

NCT07575932Phase 2Recruiting

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)

NCT07654179Not ApplicableRecruiting

Metformin as Adjunct Therapy in Depression-Obesity Comorbidity: Clinical and Genetic Evaluation

NCT07353931Phase 3Recruiting

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

NCT05770570Phase 2Recruiting

Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)

NCT07708064Not ApplicableRecruitingPrimary

Testing Just-in-Time Adaptive Interventions (JITAIs) to Prevent Goal Disengagement in Response to Weight Regain

NCT05234125Not ApplicableRecruitingPrimary

Better Lifestyle Counseling for African American Women During Pregnancy

NCT07690826Phase 2Not Yet RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity

NCT05616013Phase 2Completed

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

NCT07594093Phase 1RecruitingPrimary

Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity

NCT07499050Phase 1Recruiting

A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight

NCT07685808Phase 2Not Yet RecruitingPrimary

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

NCT04297592Phase 4Enrolling By Invitation

Antibiotic Prophylaxis in High-Risk Arthroplasty Patients

NCT06128265Not ApplicableCompletedPrimary

Sleep Extension or Regularity to Reduce Diabetes Risk

NCT07079046Not ApplicableCompleted

Efficacy of Satisens® in Reducing Emotional Eating

NCT07376655Not ApplicableRecruiting

Effect of the Thrive AI Health App on Lifestyle Behaviors and Quality of Life

NCT07431086Phase 2Active Not RecruitingPrimary

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

NCT06864026Phase 4Recruiting

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

NCT03997422Not ApplicableActive Not Recruiting

Hepatic Energy Fluxes in NASH and NAS Patients

Scroll to load more

Research Network

Activity Timeline